Clinical trials: Allergic Conjunctivitis
Allergic Conjunctivitis
Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis
The purpose of this study is to evaluate patient perceptions of olopatadine 0.2% dosed once daily in patients previously treated with twice-daily, topical, ocular, anti-allergy medications.
- Trial name
- NCT01159769
- Testing
- Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)
- Volunteers
- 215 people
- Sponsor
- Alcon Research
Allergic Conjunctivitis
Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge
The purpose of this study is to evaluate the efficacy of loteprednol etabonate ophthalmic base, compared to loteprednol etabonate ophthalmic suspension, and vehicle in the prevention of the signs and symptoms of allergic…
- Trial name
- NCT01107405
- Testing
- Loteprednol etabonate base (QD), Loteprednol etabonate base (BID), Loteprednol etabonate base (QID)
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Bausch & Lomb Incorporated
Seasonal Allergic Conjunctivitis
Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)
This study is to evaluate the safety and efficacy of Alrex (LE ophthalmic suspension, 0.2%) versus Patanol (olopatadine hydrochloride ophthalmic solution, 0.1%) in the temporary relief of the signs and symptoms of Seasonal…
- Trial name
- NCT01435460
- Testing
- Loteprednol etabonate 0.2%, Olopatadine 0.1%
- Where
- Singapore
- Volunteers
- 300 people
- Sponsor
- Bausch & Lomb Incorporated